类风湿关节炎患者基因多态性与甲氨蝶呤疗效及不良反应的相关性研究被引量：3

导出

摘要 RA是一类以不可逆性对称性多关节骨质破坏为主要特点的自身免疫性疾病,其具有严重的致残性及易复发性,目前DMARDs在缓解病情、阻止关节结构继续破坏等方面起到极其重要的作用,而甲氨蝶呤以廉价、高效、安全性高等优点现已成为DMARDs中首选药物。大量临床试验表明甲氨蝶呤的疗效及不良反应存在较大的个体化差异,目前无论是单用甲氨蝶呤或联合其他药物治疗仍有高达30％的RA患者因药物耐受或产生不良反应而无法获得满意疗效。因此寻找一种可以预测疗效及不良反应的标志物,对于实现个体化治疗显得尤为重要。近年来随着全基因组关联分析（GWAS）技术广泛应用,基因多态性与药物疗效及不良反应间的相关性已成为研究热点。本文将对甲氨蝶呤的作用机制及目前发现的甲氨蝶呤疗效及不良反应相关性基因进行阐述。

作者李欣郝立然李小峰王彩虹

机构地区山西医科大学第二医院风湿免疫科

出处《中华风湿病学杂志》 CAS CSCD 北大核心 2015年第8期563-566,共4页 Chinese Journal of Rheumatology

关键词相关性基因不良反应甲氨蝶呤预测疗效基因多态性关节炎患者类风湿 DMARDS

分类号 R593.22 [医药卫生—内科学]

引文网络
相关文献

参考文献24

1Varani K, Vincenzi F, Tosi A, et al. Expression and functional role of adenosine receptors in regulating inflammatory responsesin human synoviocytes[J]. Br J Pharmacol, 2010, 160(1): 101- 115.
2Milne GR, Palmer TM. Anti-inflammatory and immunosuppres- sive effects of the A2A adenosine receptor[J]. Sci World J, 2011, 11(1): 320-339.
3Drozdzik M, Rudas T, Pawlik A, et al. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis[J]. Pharmacogenomics J, 2007, 7(6): 404- 407.
4Samara SA, Irshaid YM, Mustafa KN. Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in jordanian rheuhaatoid arthritis patients[J]. Int J Clin Pharmacol Ther, 2014, 52(9): 746-755.
5?wierkot J, Slszak R, Karpifiski P, et al. Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR, TYMS and TC Ⅱ and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis[J]. Pol Arch Med Wewn, 2015, 125(3): 152-161.
6蔡静,徐建华.类风湿关节炎患者转运蛋白基因多态性与甲氨蝶呤疗效及安全性的相关性研究进展[J].中国临床药理学杂志,2010,26(3):231-235. 被引量：3
7Kato T, Hmuada A, Mori S, et al. Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese pa- tients with rheumatoid arthritis[J]. Drug Metab Pharmacokinet, 2012, 27(2): 192-199.
8Hayashi H, Fujimaki C, Daimon T, et al. Genetic polymor- phisms in folate pathway enzymes as a possible marker for pre- dicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis[J]. J Clin Pharm Ther, 2009, 34(3): 355-361.
9Jekic B, Lukovic L, Bunjevacki V, et al. Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients[J]. Eur J Clin Pharmacol, 2013, 69(3): 377-383.
10Senapati S, Singh S, Das M, et al. Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation [J]. Pharmacogenet Genomics, 2014, 24(4): 211-219.

二级参考文献45

1Urano W,Taniguchi A,Yamanaka H,et al.Polymorphisms in the methylenetetrahydrofolate reductase gent were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis,as evidenced by single locus and haplotype analyses[J].Pharmacogenetics,2002 ; 12:183-190.
2Wessels JA,deVries-Bouwstra JK,Heijmans BT,et al.Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes[J].Arthritis Rheum,2006 ;54:1087-1095.
3Wada M.Single nucleotide polymorphisma in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response[J].Cancer Lett,2006 ;234:40-50.
4Hediger MA,Romero MF,Peng JB,et al.The ABCs of solute carriers:physiological,pathological and therapeutic implications of human membrane transport proteins Introduction[J].Pfluegers Arch,2004 ;447:465-468.
5Hooijberg JH,Broxterman HJ,Kool M,et al.Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2[J].Cancer Res,1999 ;59:2532-2535.
6Ken-ichi H,Keiko F,Masanori T,et al.Involvement of reduced folate carrier 1 in the inner blood-retinal barrier transport of methyltetrahydrofolate[J].Drug Metab Pharmacokinet,2008;23:285-292.
7Brzezinska A,Winska P,Balinska M,et al.Cellular aspects of folate and antffolate membrane transport[J].Acta Biochim Pol,2000; 47:735-749.
8Chango A,Emery-Fillon N,de Courcy GP,et al.A polymorphism (80G-》A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia[J].Mol Genet Metab,2000; 70:310-315.
9Prabha R,Howard L Methotrexate pharmacogenetics:the first step toward individualized therapy in rheumatoid arthritts[J].Arthrit Rheumat,2006 ;54:1366-1377.
10Gerrit J,Joost von der H,Ruud O,et al.Sulfasalzine is a potent inhibitor of the reduced folate carrier.Implications for combination therapies with methotrexate in reumatoid arthritis[J].Arthrit Rheumat,2004;50:2130-2139.